References
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496–509.
Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008; 35: 883–90.
Andreadou E, Kemanetzoglou E, Brokalaki C, et al. Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature. Case Rep Neurol Med 2013; 2013: 671935.
Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O. Anti-Tumor Necrosis Factor-alpha Induced Systemic Lupus Erythematosus. Open Rheumatol J 2012; 6: 315–9.
Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis 2010; 69: 1691–3.
Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis. Lancet 2001; 358: 1784.
Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001; 44: 1977–83.
Hua Y, Wu J, Keep RF, Nakamura T, Hoff JT, Xi G. Tumor necrosis factor-alpha increases in the brain after intracerebral hemorrhage and thrombin stimulation. Neurosurgery 2006; 58: 542–50.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Honda, Y., Otsuka, A., Egawa, G. et al. Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-α therapy in psoriatic arthritis. Eur J Dermatol 25, 487–488 (2015). https://doi.org/10.1684/ejd.2015.2558
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2015.2558